FY2025 EPS Forecast for Olema Pharmaceuticals Cut by Analyst

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) – Investment analysts at Lifesci Capital reduced their FY2025 earnings estimates for shares of Olema Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 19th. Lifesci Capital analyst S. Slutsky now expects that the company will post earnings of ($2.28) per share for the year, down from their previous estimate of ($2.12). The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.33) per share.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its quarterly earnings results on Tuesday, March 18th. The company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.12.

OLMA has been the topic of several other reports. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Olema Pharmaceuticals in a report on Wednesday. Oppenheimer reiterated an “outperform” rating and set a $25.00 price target (down from $30.00) on shares of Olema Pharmaceuticals in a research note on Wednesday.

Olema Pharmaceuticals Trading Up 0.2 %

Shares of OLMA opened at $4.12 on Friday. The firm has a market cap of $236.07 million, a P/E ratio of -1.88 and a beta of 2.11. Olema Pharmaceuticals has a 12-month low of $3.94 and a 12-month high of $16.62. The company’s 50-day moving average price is $5.11 and its 200 day moving average price is $8.40.

Insider Transactions at Olema Pharmaceuticals

In related news, major shareholder Bain Capital Life Sciences Inv acquired 300,000 shares of the stock in a transaction dated Wednesday, January 8th. The stock was acquired at an average cost of $5.76 per share, with a total value of $1,728,000.00. Following the completion of the transaction, the insider now owns 7,800,000 shares in the company, valued at $44,928,000. This represents a 4.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 19.40% of the company’s stock.

Hedge Funds Weigh In On Olema Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. boosted its holdings in shares of Olema Pharmaceuticals by 658.7% in the third quarter. JPMorgan Chase & Co. now owns 181,032 shares of the company’s stock valued at $2,162,000 after acquiring an additional 157,171 shares during the period. Victory Capital Management Inc. raised its stake in shares of Olema Pharmaceuticals by 9.9% during the third quarter. Victory Capital Management Inc. now owns 851,512 shares of the company’s stock worth $10,167,000 after purchasing an additional 76,720 shares during the last quarter. Hennion & Walsh Asset Management Inc. raised its stake in shares of Olema Pharmaceuticals by 80.5% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 212,246 shares of the company’s stock worth $1,237,000 after purchasing an additional 94,651 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Olema Pharmaceuticals by 168.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 330,761 shares of the company’s stock worth $3,949,000 after purchasing an additional 207,565 shares during the last quarter. Finally, Wellington Management Group LLP raised its stake in shares of Olema Pharmaceuticals by 10.8% during the third quarter. Wellington Management Group LLP now owns 1,002,685 shares of the company’s stock worth $11,972,000 after purchasing an additional 97,428 shares during the last quarter. 91.78% of the stock is owned by institutional investors and hedge funds.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.